Japanese pharmaceutical company Eisai has partnered with UK-based pharmaceutical and services firm Clinigen Group to distribute Halaven (eribulin) in South Africa for the treatment of women with metastatic breast cancer.

The product will be provided through Clinigen's division Link Healthcare, which was acquired by the firm in 2015.

Discovered and developed by Eisai, Eribulin is a synthetic variant of microtubule dynamics inhibitor halichondrin B, designed to inhibit the growth phase of microtubule dynamics to prevent cell division.

Halaven is currently available in South Africa for the treatment of women with locally advanced or metastatic breast cancer who have received at least two chemotherapeutic regimens for their advanced disease.

"This launch builds on our strong relationship with Eisai, allowing us to further demonstrate our local distribution knowledge and expertise."

The prior therapy of these patients should have included an anthracycline and a taxane unless patients were not suitable for these treatments.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

See Also:

Clinigen group chief executive officer Shaun Chilton said: "This is the first distribution agreement of its kind for Clinigen following our acquisition of Link Healthcare in 2015, and provides access to eribulin in South Africa.

"This launch builds on our strong relationship with Eisai, allowing us to further demonstrate our local distribution knowledge and expertise.”

A clinical trial (EMBRACE) conducted to evaluate eribulin in patients with metastatic breast cancer found that it can prolong median overall survival when compared to an alternative treatment of physician’s choice by 2.5 months.

Eribulin is currently indicated in the European Union (EU) for the treatment of adults with locally advanced or metastatic breast cancer and for adult patients with unresectable liposarcoma.